Google to Verify
Lovaza has also been demonstrated to reduce VLDL-cholesterol and non-HDL-cholesterol, and increase HDL-cholesterol. But, it can raise LDL-cholesterol up to 45% Vascepa will undoubtedly become a major competitor for Lovaza. In clinicial trials, Vascepa was shown to lower triglycerides; while Lovaza also lowers the triglyceride concentration, Vascepa also lowers LDL-C; Lovaza does not. Lovaza was approved to treat people with very high triglyceride levels ( 500 mg/dl), Vascepa is also approved for this market; however the company has also demonstrated that the drug can impact levels in people with high triglyceride ( 200 mg/dl and
not ONLY does AMRN Drug Lower LDL , AMRN Drug Can be used with all levels lowest to highest of patients with high cholesterol // Lovaza RAISES LDL 45% AND CAN ONLY BE USED with high level cholesterol patients. AMRN is Clearly going to be the winner.